Innate Immunotherapeutics Report issue

For profit Phase 2
Founded: Sydney Australia (2000)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2007
NCT00385567
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Virionyx Corporation Limited

Active Ingredients

Drugs in Phase 2 Trials (3)

mis416 (2 trials)

pehrg214 (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

HIV Infections (Phase 2)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Chronic Progressive (Phase 2)

Neoplasm Metastasis (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3